Implications of p53 in growth arrest and apoptosis on combined treatment of human mammary epithelial cells with topotecan and UCN-01

Journal of Experimental Therapeutics and Oncology

Volumn 4, Issue 3, 2004, Pages 213-222

  Redkar, Alka ^a   Mixter, Phillip ^a   Daoud, Sayed S ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Breast cancer; Cell cycle; P53; Topotecan; UCN 01

Indexed keywords

7 HYDROXYSTAUROSPORINE; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; DOUBLE STRANDED DNA; PROTEIN P53; TOPOTECAN;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DNA STRAND BREAKAGE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG POTENTIATION; FLOW CYTOMETRY; GROWTH DISORDER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST; BREAST NEOPLASMS; CARCINOMA; CELL CYCLE; CELL PROLIFERATION; EPITHELIAL CELLS; FEMALE; GENES, P53; HUMANS; STAUROSPORINE; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 9344248431     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Levine A J. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997
2. Lu X, Lane DP. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes. Cell 75: 765-778, 1993
3. Colman MS, Afshari CA, Barrett JC. Regulation of p53 stability and activity in response to genotoxic stress. Mutant Res 462: 179-188, 2000
4. Livingston LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53. Cell 70: 923-935, 1992.
5. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70: 937-948, 1992
6. Bouffler SD, Kemp CJ, Balmain A, Cox R. Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice. Cancer Res 55: 3883-3889, 1995.
7. Havre PA, Yuan J, Hedrick L, Cho KR, Glazer PM. p53 inactivation by HPV16E6 results in increased mutagenesis in human cells. Cancer Res 55: 4420-4424, 1995.
8. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Witts RE, Paull KD. An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343-349, 1997
9. Mcilwrath AJ, Vasey PA, Ross GM, Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines: Dependence on wild-type p53 for radiosensitivity. Cancer Res 54: 3718-3722, 1994
10. Kondo S, Barnett GH, Hara H, Morimura T, Takeuchi J. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 10: 2001-2006, 1995
11. Fan S, Cherney B, Reinhold W, Rucker K, O'Conner PM. Disruption of p53 function in immortalized human cells does not affect survival or apoptosis after taxol or vincristine treatment. Clin Cancer Res 4: 1047-1054, 1998
12. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA. Introduction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54: 2287-2291, 1994
13. Blagosklonny MV, El-Deiry WS. Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. Int J Cancer 75: 933-940, 1998
14. Ju JF, Banerjee D, Lenz HJ, Danenberg KD, Schmittgen TC, Spears CP, Schonthal AH, Manno DJ, Hochhauser D, Bertino JR, Danenberg PV. Restoration of wild-type p53 activity in p53-null HL60 cells confers multidrug sensitivity. Clin Cancer Res 4: 1315-1322, 1998
15. Kollmansberger C, Mross K, Jakob A, Kanz L, Bokemeyer C. Topotecan, A novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 56: 1-12, 1999
16. Takahashi I, Kobayashi E, Asano K, Yoshida M, Nakana H. UCN-01, a selective inhibitor of protein kinase C from Streptomyces. J. Antibiot 40: 1782-1784, 1987
17. Wang Q, Worland P, Clark JL, Carlson BA, Sausville EA. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ. 6: 927-936, 1995
18. Kawakami K, Futami H, Takahara J, Yamaguchi K. UCN-01 (7-hydroxyl-staurosporine) inhibits kinase activity of cyclin-dependent kinases and reduces phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res 219: 778-793, 1996
19. Akinaga S, Gomi K, Morimoto M, Tamaoki T, Okabe M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 51: 4888-4892, 1991
20. Seynaeve CM, Stetler-Stevenson M, Sebers S, Kaur G, Sausville EA, Worland PJ. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 53: 2081-2086, 1993
21. Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 19: 2319-2333, 2001
22. Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-check point inhibitor. Clin Cancer Res 2: 791-797, 1996
23. Akinaga S, Nomura K, Gomi K, Okabe M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol 32: 183-189, 1993
24. Jones CB, Clements MK, Wasi S, Daoud SS. Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G2 arrest. Cancer Chemother. Pharmacol. 45: 252-258, 2000
25. Wang Q, Fan S, Eastman A, Worland P, Sausville EA, O'Conner PM. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. JNCI 88: 956-965, 1996
26. Graves PR, Yu L, Schwarz JK, Gales J, Sausville, E A, O'Connor PM, Piwnica-Worms H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 275: 5600-5605, 2000
27. Busby EC, Leistritz, DF, Abraham R T, Karnitz L M, Sarkaria, J N. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint hChk1. Cancer Res 60: 2108-2112, 2000
28. Jones, CB, Clements MK, Wasi S, Daoud SS. Sensitivity to camptothecin of human breast cancer cells and normal bovine endothelial cells, in vitro. Cancer Chemother Pharmacol 40: 475-483, 1997
29. Wang Y, Perrault AR, Iliakis G. Down regulation of DNA replication in extracts of camptothecin-treated cells: activation of an S-phase checkpoint. Cancer Res 57: 1654-9, 1997.
30. Goldwasser F, Shimizu T, Jackman J Hoki Y, O'Conner PM, Kohn KW, Pommier Y. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells Cancer Res 56: 4430-7, 1996
31. Foster SA, Demers GW, Etscheid BG, Galloway DA. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol 68: 5698-5705, 1994.
32. Foster SA, Wong DJ, Barren MT, Galloway, D.A. Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol 18: 1793-1801, 1998.
33. Jones CB, Clements MK, Redkar A, Daoud SS. UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cells. Int J Oncol 17: 1043-51, 2000.
34. Daoud SS and Forde NH. Synergistic cytotoxic actions of cisplatin and liposomal valinomycin on human ovarian carcinoma cells. Cancer Chemother Pharmacol 28: 370-376, 1991.
35. Greenblatt MS, Bennett, W P, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene-clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-78, 1994.
36. Lai H, Lin L, Nadji M, Lai S, Trapido E, Meng L. Mutations in the p53 tumor suppressor gene and early onset of breast cancer. Cancer Biol Ther 1 (1): 31-6, 2002
37. Marchetti P, Cannita K, Ricevuto E, De Galitis F, Di Rocco ZC, Tessitore A, Bisenga R, Pozzio G, De Rubeis GP, Ventura T, Martinotti S, Ficorella C. Prognostic value of p53 molecular status in high-risk primary breast cancer. Ann Oncol 14(5): 704-8, 2003
38. Redkar A, Meadows GG, Daoud SS. UCN-01 dose-dependent inhibition of hyperproliferative normal tissues in mice. Int J Oncol 19: 193-9, 2001.